News Releases

News Releases

  • Sep 25, 2017

    Summary ToggleCo-Diagnostics, Inc. to Present at Robins Equity Research Roundup 2017

    SALT LAKE CITY --(BUSINESS WIRE)--Sep. 25, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that it will be presenting at the Third Annual
  • Sep 07, 2017

    Summary ToggleCo-Diagnostics, Inc. to Present at NewsMakers Conference 2017

    SALT LAKE CITY --(BUSINESS WIRE)--Sep. 7, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that CEO Dwight Egan will represent Co-Diagnostics
  • Sep 05, 2017

    Summary ToggleCo-Diagnostics, Inc. to Sign Purchase Agreement with MEDCIS Pathlabs

    SANDY, Utah --(BUSINESS WIRE)--Sep. 5, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, and MEDCIS Pathlabs India Pvt. Ltd.
  • Aug 24, 2017

    Summary ToggleCo-Diagnostics, Inc. Strengthens Zika Customer Base in Caribbean Basin

    Sales expected upon successful performance evaluation and validation SANDY, Utah --(BUSINESS WIRE)--Aug. 24, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests,
  • Aug 22, 2017

    Summary ToggleCo-Diagnostics, Inc. CEO to Present at 2017 SALSS

    SALT LAKE CITY --(BUSINESS WIRE)--Aug. 22, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, announced today that CEO Dwight Egan will be a presenter at the
  • Aug 10, 2017

    Summary ToggleCo-Diagnostics, Inc. to Undergo ISO 13485:2016 Audit

    Audit to prepare for eventual sales into the US market SALT LAKE CITY --(BUSINESS WIRE)--Aug. 10, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, will be
  • Aug 02, 2017

    Summary ToggleCo-Diagnostics, Inc. to Attend AACC 2017

    SALT LAKE CITY --(BUSINESS WIRE)--Aug. 2, 2017-- Co-Diagnostics , Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company with a unique, proprietary platform for the development of diagnostic tests, will be sending Company representatives on August 2-3, 2017 , to
  • Jul 27, 2017

    Summary ToggleCo-Diagnostics, Inc. Verifies Zika CoPrimer™ Test

    SALT LAKE CITY, July 27, 2017 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ: CODX ) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, has completed principle design and verification of its Zika
  • Jul 25, 2017

    Summary ToggleCo-Diagnostics, Inc. Announces Joint Venture in India

    SALT LAKE CITY--( BUSINESS WIRE )--Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has a unique, proprietary platform for the development of diagnostic tests, officially announced today the recent incorporation of CoSara Diagnostics,
  • Jul 17, 2017

    Summary ToggleCo-Diagnostics, Inc. to Use IPO Proceeds to Expand Operations

    Salt Lake City, UT – July 17, 2017 – Co-Diagnostics, Inc. (NASDAQ: CODX) (“Co-Diagnostics” or the “Company”), a molecular diagnostics company that has developed and intends both to manufacture and sell reagents used for diagnostic tests, has completed its initial public offering and started trading